Just to add to Tada’s points regarding ASSURE don’t forget that the subset of participants on Crestor + Apabetalone had plaque reduction of 1.43% in the 6 month trial. Assuming straighlined annualized responses (which is a big assumption) that’s roughly a 14 fold improvement over high dose Crestor alone. I could never understand why the differentiation between Crestor and Lipitor when combined with Apabetalone was never a prespecified end point in ASSURE but none the less I agree that the company should be reminding the market of these types of achievement. To me this lack of attention to detail and consistency is sadly the norm for the business side of RVX.